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Despite the implementation of cervical
cytology screening programs over 50
years ago, cervical cancer remains the
second most common cause of cancer
death in women worldwide. The etiologi-
cal role of human papillomavirus (HPV)
infection in the development of anogeni-
tal cancers has been firmly established,
and epidemiologic research indicates
that genital HPV infections are wide-
spread among adults who have been
sexually active and have the highest inci-
dence of any sexually transmitted dis-
ease (STD) in the United States (Cates,
1999). More than 100 different HPV
genotypes have been identified and
approximately 30 have been shown to
have a propensity to infect anogeni-
tal tract tissues. Mucosotropic HPVs
are grouped into low-risk or high-
risk categories on the basis of each
genotype’s association with a
benign or malignant disease
process, and high-risk HPV DNA is
detected in more than 99% of all
cancers of the uterine cervix
(Walboomers et al., 1999). Although
most anogenital HPV infections are
transient, persistent infection with a
high-risk HPV is associated with
anogenital cancers (Wallin et al.,
1999). HPV type 16 (HPV-16) is the
type most commonly linked with
cancer and is detected in over 50%
of invasive cervical cancers and
high-grade cervical intraepithelial
neoplasias (CIN), and in 25% of
low-grade CIN.
Koutsky et al.’s recent report of
an effective prophylactic HPV-16
vaccine that prevents the subse-
quent development of CIN culmi-
nates more than two decades of
extensive preclinical and clinical
research (Koutsky et al., 2002). The
vaccinated women in this study were
not only protected from developing
preinvasive disease associated with
HPV-16, but also from persistent and
transient genital HPV infection. In
essence, by neutralizing HPV-16, the
vaccine prevents the causative agent
from residing in the anogenital tract,
thereby reducing the risk of subsequent
sexual transmission.
Efforts to develop a vaccine to pre-
vent persistent HPV infection have
focused on eliciting humoral immune
responses to the HPV capsid proteins
using synthetic empty capsids, termed
“virus-like particles” (VLPs). The L1
(major capsid protein) organizes itself
into naked icosahedrons when it is
expressed at high levels in microbial or
cellular expression systems using
recombinant techniques (Schiller and
Lowy, 2001) (Figure 1). These VLPs are
morphologically indistinguishable from
the authentic virion, are non-infectious,
and lack any oncogenic DNA. Preclinical
studies in animals demonstrated that
vaccination with species-specific VLP
induced neutralizing antibodies that
were also effective in preventing the
development of HPV-induced lesions. In
early clinical studies, HPV-16 L1 VLPs
were well tolerated and induced neutral-
izing anti-HPV-16 antibodies (Harro et
al., 2001).
Humoral immunity to VLP-based
vaccines is not only species specific but
also type specific, although divergent
variants of HPV types are serologically
crossreactive. Since several HPV types
are consistently detected in anogenital
cancers, a multivalent vaccine is a ratio-
nal next step for future clinical trials.
Because about 70% of HPV-associated
cervical cancers contain either HPV-16
or -18, inclusion of at least these two
types would be highly desirable. If a mul-
tivalent vaccine containing VLPs for
HPV-16, -18, -31, -33, and -45 were
developed, approximately 85% of cervi-
cal cancers could theoretically be pre-
vented (Walboomers et al., 1999).
The inclusion of HPV-6 and -11,
which cause most genital warts, in a
multivalent vaccine might also
increase the utilization of a genital
HPV vaccine by members of both
genders, thereby promoting “herd”
immunity.
To emphasize the potential
importance of Koutsky et al.’s recent
report, consider the impact that the
hepatitis B vaccine program has
had on the incidence of hepatocel-
lular carcinoma, a cancer causally
linked with hepatitis B and previous-
ly one of the most common cancers
in man. Following the universal vac-
cine program targeting neonates in
Taiwan since 1984, the prevalence
of childhood hepatitis in that coun-
try has decreased by almost 90%,
the morbidity has decreased by
nearly 80%, and the incidence of
hepatocellular carcinoma has
declined by a factor of four (Huang
and Lin, 2000).
Since most sexually active
women have already been exposed
to HPV, it is unlikely that humoral
immunity induced from a VLP-
based HPV vaccine will be effective in
treating women who have already been
infected. For example, VLPs were inef-
fective in the treatment of established
lesions in several animal studies. This is
not surprising, since VLPs induce neu-
tralizing antibodies that circulate in the
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Figure 1. The icosahedral assembly of the HPV-16 L1 VLP
The naked icosahedrons are composed of an ordered
array of 72 L1 pentamers. Twelve identical pentamers are
shown in this assembly, each in a different color. This figure
was reprinted from Chen et al., 2000.
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serum and recognize extracellular anti-
gens or antigens born on the surface of a
cell. The life cycle of an established HPV
infection is characteristically intracellular,
noncytopathic, and nonlytic. Therefore,
therapeutic vaccines are being devel-
oped to eradicate existing disease or
infection by eliciting cell-mediated
immune responses targeting cells
expressing tumor-associated or tumor-
specific antigens on their surface. For
cervical cancer, the viral peptides
derived from high-risk HPV E6 and E7
oncoproteins are the tumor-specific anti-
gens because the viral genes encoding
E6 and E7 are selectively retained and
expressed during malignant progression
of virally induced neoplastic lesions. A
wide variety of immunologic approaches
are candidates for therapeutic, antitumor
vaccines. In general, there are four broad
categories of therapeutic vaccine strate-
gies: peptide-based, protein-based,
nucleic acid based, and cell-based.
Therapeutic vaccination has enormous
clinical implications and is being investi-
gated intensively (see Steller, 2002 for a
review).
As impressive as VLPs seem to be
for preventing papillomavirus infections
and subsequent diseases, this technolo-
gy’s potential for also treating established
lesions is perhaps of surpassing impor-
tance (Schiller and Lowy, 2001). To
increase their therapeutic potential,
polypeptides of the nonstructural viral
genes have been incorporated within the
VLPs as a genetic fusion with either the
major (L1) or minor (L2) capsid proteins.
These chimeric VLPs, which are
morphologically indistinguishable from
their parental VLPs, induce cell-mediated
immune responses to the fused polypep-
tides contained within it. Chimeric VLPs
containing HPV-16 E7 polypeptides have
been shown to induce potent cytotoxic T-
lymphocyte responses and to induce the
regression of established tumors
(Schafer et al., 1999). Recent investiga-
tions also indicate that VLPs specifically
bind to dendritic cells (antigen-presenting
cells) and induce their activation (Rudolf
et al., 2001). Since chimeric VLPs retain
the conformational L1 surface epitopes
required for inducing neutralizing anti-
bodies, they may ultimately be developed
as a combined prophylactic and thera-
peutic vaccine. Furthermore, non-HPV
antigens can be incorporated within the
VLPs, raising the possibility that chimeric
VLPs may be useful as vehicles for the
delivery of antigens to treat non-HPV
associated diseases.
Several important issues require
careful consideration before anti-HPV
vaccines become available for mass
immunization programs. Female genital
HPV infection occurs commonly and cer-
vical cancer remains a leading cause of
cancer-related death in women world-
wide, but cervical cancer does not devel-
op in the vast majority of women infected
with HPV.Therefore, very few women are
likely to benefit from the protective
effects of a prophylactic HPV vaccine
when the aim is to prevent the develop-
ment of cervical cancer. However, an
effective vaccine might dramatically
reduce the cost of, and possibly elimi-
nate the need for, screening and surveil-
lance programs, and there would be a
clear benefit in the unscreened popula-
tion. The timing of vaccine delivery is
another important issue since a success-
ful prophylactic vaccine will only be effec-
tive when it is administered to women
before they acquire HPV infection
through sexual activity. Like hepatitis B
(which is also sexually transmitted),
should a prophylactic HPV vaccine be
administered universally during child-
hood? To enhance overall effectiveness
and diminish transmission rates, the vac-
cine should ideally also be administered
to males, even though they rarely mani-
fest HPV-associated malignancies.
Because of the large lag-time from
incident HPV infection to the develop-
ment of invasive cervical cancer, it will
take several years before the impact of
an effective vaccine to prevent cervical
cancer can be clinically appreciated. For
instance, in North American women,
incident genital HPV infection usually
occurs during the late-teen age years,
yet the mean age of women diagnosed
with cervical cancer is 53. Following well-
done, long-term clinical studies, the true
effectiveness of anti-HPV vaccines and
their real impact on HPV-associated dis-
eases will hopefully be demonstrated.
Such a vaccine should gradually have a
profound effect on health care resource
allocation and potentially represents yet
another medical advance that will shift
human demographics.
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